Dataset Information
Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial.
Ontology highlight
ABSTRACT: Background
Oxidative stress is highly prevalent in patients with end-stage renal disease and is linked to excess cardiovascular risk. Identifying therapies that reduce oxidative stress has the potential to improve cardiovascular outcomes in patients undergoing maintenance dialysis.Study design
Placebo-controlled, 3-arm, double-blind, randomized, clinical trial.Setting & participants
65 patients undergoing thrice-weekly maintenance hemodialysis.Intervention
Patients were randomly assigned in a 1:1:1 ratio to receive once-daily coenzyme Q10 (CoQ10; 600 or 1,200mg) or matching placebo for 4 months.Outcomes
The primary outcome was plasma oxidative stress, defined as plasma concentration of F2-isoprotanes. Secondary outcomes included levels of plasma isofurans, levels of cardiac biomarkers, predialysis blood pressure, and safety/tolerability.Measurements
F2-isoprostanes and isofurans were measured as plasma markers of oxidative stress, and N-terminal pro-brain natriuretic peptide and troponin T were measured as cardiac biomarkers at baseline and 1, 2, and 4 months.Results
Of 80 randomly assigned patients, 15 were excluded due to not completing at least 1 postbaseline study visit and 65 were included in the primary intention-to-treat analysis. No treatment-related major adverse events occurred. Daily treatment with 1,200mg, but not 600mg, of CoQ10 significantly reduced plasma F2-isoprostanes concentrations at 4 months compared to placebo (adjusted mean changes of -10.7 [95% CI, -7.1 to -14.3] pg/mL [P<0.001] and -8.3 [95% CI, -5.5 to -11.0] pg/mL [P=0.1], respectively). There were no significant effects of CoQ10 treatment on levels of plasma isofurans, cardiac biomarkers, or predialysis blood pressures.Limitations
Study not powered to detect small treatment effects; difference in baseline characteristics among randomized groups.Conclusions
In patients undergoing maintenance hemodialysis, daily supplementation with 1,200mg of CoQ10 is safe and results in a reduction in plasma concentrations of F2-isoprostanes, a marker of oxidative stress. Future studies are needed to determine whether CoQ10 supplementation improves clinical outcomes for patients undergoing maintenance hemodialysis.
SUBMITTER: Rivara MB
PROVIDER: S-EPMC5616172 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
Publications
Effect of Coenzyme Q<sub>10</sub> on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ<sub>10</sub> Biomarker Trial.
American journal of kidney diseases : the official journal of the National Kidney Foundation 20161204 3
<h4>Background</h4>Oxidative stress is highly prevalent in patients with end-stage renal disease and is linked to excess cardiovascular risk. Identifying therapies that reduce oxidative stress has the potential to improve cardiovascular outcomes in patients undergoing maintenance dialysis.<h4>Study design</h4>Placebo-controlled, 3-arm, double-blind, randomized, clinical trial.<h4>Setting & participants</h4>65 patients undergoing thrice-weekly maintenance hemodialysis.<h4>Intervention</h4>Patient ...[more]